Herbal hepatotoxicity

Stickel, Felix; Patsenker, E.; Schuppan, Detlef

doi:10.1016/j.jhep.2005.08.002

Cited by 236 publications

(200 citation statements)

References 77 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Hepatotoxicity is an important issue when investigating the safety of medications, and many herbal medications do affect the liver (Bunchorntavakul, 2013;Stickel, 2005;Teschke, 2012). Nevertheless, in this study there were only few reports of hepatotoxicity (4 of 75 cases), and this is in contrast to the literature.…”

Section: Discussionmentioning

confidence: 61%

Adverse Effects of Plant Food Supplements and Plants Consumed as Food: Results from the Poisons Centres-Based PlantLIBRA Study

et al. 2016

View full text Add to dashboard Cite

Plant food supplements (PFS) are products of increasing popularity and wide-spread distribution. Nevertheless, information about their risks is limited. To fill this gap, a poisons centres-based study was performed as part of the EU project PlantLIBRA. Multicentre retrospective review of data from selected European and Brazilian poisons centres, involving human cases of adverse effects due to plants consumed as food or as ingredients of food supplements recorded between 2006 and 2010. Ten poisons centres provided a total of 75 cases. In 57 cases (76%) a PFS was involved; in 18 (24%) a plant was ingested as food. The 10 most frequently reported plants were Valeriana officinalis, Camellia sinensis, Paullinia cupana, Melissa officinalis, Passiflora incarnata, Mentha piperita, Glycyrrhiza glabra, Ilex paraguariensis, Panax ginseng, and Citrus aurantium. The most frequently observed clinical effects were neurotoxicity and gastro-intestinal symptoms. Most cases showed a benign clinical course; however, five cases were severe. PFS-related adverse effects seem to be relatively infrequent issues for poisons centres. Most cases showed mild symptoms. Nevertheless, the occurrence of some severe adverse effects and the increasing popularity of PFS require continuous active surveillance, and further research is warranted. Most cases showed a benign clinical course; however, five cases were severe. Conclusions:PFS-related adverse effects seem to be relatively infrequent issues for poisons centres. Most cases showed mild symptoms. Nevertheless, the occurrence of some severe adverse effects and the increasing popularity of PFS require continuous active surveillance, and further research is warranted.

show abstract

Section: Discussionmentioning

confidence: 61%

Adverse Effects of Plant Food Supplements and Plants Consumed as Food: Results from the Poisons Centres-Based PlantLIBRA Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…52 Second, the liberal use of poorly standardized crude extracts or complex mixtures of botanicals poses an increased risk of hepatotoxicity. 54 As a result, only a few botanicals are currently in recognized clinical trials, including the flavonoids silymarin or silibinin from milk thistle for patients with chronic hepatitis C or nonalcoholic steatohepatitis 55 (see http://clinicaltrials-.gov/ for a complete list). Drug Repositioning.…”

Section: Antifibrotic Drug Developmentmentioning

confidence: 99%

Targeting Liver Fibrosis

2009

Self Cite

View full text Add to dashboard Cite

We have made striking progress in our understanding of the biochemistry and cell biology that underlies liver fibrosis and cirrhosis, including the development of strategies and agents to prevent and reverse fibrosis. However, translation of this knowledge into clinical practice has been hampered by (1) the limitation of many in vitro and in vivo models to confirm mechanisms and to test antifibrotic agents, and (2) the lack of sensitive methodologies to quantify the degree of liver fibrosis and the dynamics of fibrosis progression or reversal in patients. Furthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fibrosis and fibrosis progression alone are merely plausible surrogates for future clinical deterioration. In this review we focus on an optimized strategy for preclinical antifibrotic drug development and highlight the current and future techniques that permit noninvasive assessment and quantification of liver fibrosis and fibrogenesis. The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents. (HEPATOLOGY 2009;50:1294-1306

show abstract

“…These alkaloids produce hepatotoxicity through a characteristic veno-occlusive disease that may be rapidly progressive and fatal. 39 Contaminants in herbal products may be particularly problematic in medicines imported from Asia. A study examining the contents of 260 Asian patent medicines found that 25% of products contained high levels of heavy metals and another 7% contained undeclared drugs, purposefully and illegally added to produce a desired effect.…”

Section: Safety Toxicity and Side Effectsmentioning

confidence: 99%